AZN News and Press, AstraZeneca PLC From 02/05/24

NEW YORK and SHANGHAI, China, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed a memorandum of understanding (MOU) with AstraZeneca China to establish a research and development ...

2024-02-04 09:21:56 ET Summary AstraZeneca is one of the fastest-growing pharmaceutical companies. On February 8, 2024, the company will publish financial results for the 4th quarter of 2023. From a broader perspective, AstraZeneca's EPS is expected to continue to grow through...

2024-02-04 08:45:00 ET As Wall Street embarks on the first full week of February, a large number of companies are set to release their earnings reports, providing a crucial glimpse into their financial standing and future outlook. From industry leaders like The Walt Disney Company (...

2024-02-03 11:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Global markets rallied...

2024-02-02 12:43:50 ET Summary Regeneron returned to topline growth in 2023 and this has led to the company's valuation rising to my expected EV/revenue range. The company is making significant investments in the obesity space, focusing on preserving lean mass and reducing fat mas...

2024-02-01 10:13:39 ET More on Bristol-Myers, Johnson & Johnson, etc. Pfizer Is Down 54% From Highs, Now Yields 6.1% Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disagree Wit...

2024-02-01 10:13:39 ET More on Bristol-Myers Squibb, Johnson & Johnson, etc. Pfizer Is Down 54% From Highs, Now Yields 6.1% Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disag...

2024-01-29 15:13:38 ET More on Karuna Therapeutics Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond Dopamine Karuna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call Transcript M&A activity expected to pick up in 2024, banke...

If approved, AstraZeneca and Daiichi Sankyo’s ENHERTU will potentially be the first HER2-directed treatment and antibody drug conjugate to receive a tumor-agnostic indication Application based on results from DESTINY-PanTumor02 trial and supported by additional ENHERTU data ...

2024-01-29 06:46:23 ET More on AstraZeneca Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Is Feeling The Weight Of The Market In 2023 AstraZeneca launches asthma re...